Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Catabasis Pharmaceuticals

Nasdaq:CATB
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CATB
Nasdaq
$71M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Catabasis Pharmaceuticals has significant price volatility in the past 3 months.
CATB Share Price and Events
7 Day Returns
23.8%
NasdaqGM:CATB
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-50%
NasdaqGM:CATB
1.6%
US Biotechs
-9.1%
US Market
CATB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Catabasis Pharmaceuticals (CATB) 23.8% -16.1% -32.4% -50% -75.3% -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • CATB underperformed the Biotechs industry which returned 1.6% over the past year.
  • CATB underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
CATB
Industry
5yr Volatility vs Market
Related Companies

CATB Value

 Is Catabasis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Catabasis Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $3.96.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Catabasis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Catabasis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CATB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.35
NasdaqGM:CATB Share Price ** NasdaqGM (2020-03-27) in USD $3.96
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Catabasis Pharmaceuticals.

NasdaqGM:CATB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CATB Share Price ÷ EPS (both in USD)

= 3.96 ÷ -2.35

-1.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catabasis Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Catabasis Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Catabasis Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:CATB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
66.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Catabasis Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Catabasis Pharmaceuticals's assets?
Raw Data
NasdaqGM:CATB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.87
NasdaqGM:CATB Share Price * NasdaqGM (2020-03-27) in USD $3.96
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:CATB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CATB Share Price ÷ Book Value per Share (both in USD)

= 3.96 ÷ 2.87

1.38x

* Primary Listing of Catabasis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catabasis Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Catabasis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Catabasis Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CATB Future Performance

 How is Catabasis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
66.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Catabasis Pharmaceuticals expected to grow at an attractive rate?
  • Catabasis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Catabasis Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Catabasis Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CATB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CATB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 66.8%
NasdaqGM:CATB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 65.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CATB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CATB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 419 243 2
2023-12-31 204 127 2
2022-12-31 76 25 2
2021-12-31 7 -29 2
2020-12-31 0 -29 2
2020-03-28
NasdaqGM:CATB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -27 -26
2019-09-30 -24 -26
2019-06-30 -23 -25
2019-03-31 -23 -24
2018-12-31 -23 -26
2018-09-30 0 -24 -25
2018-06-30 1 -25 -27
2018-03-31 1 -26 -27
2017-12-31 1 -27 -27
2017-09-30 0 -29 -31
2017-06-30 -29 -32
2017-03-31 -32 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Catabasis Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Catabasis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CATB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Catabasis Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CATB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 12.90 21.09 4.71 2.00
2023-12-31 6.99 13.15 0.82 2.00
2022-12-31 1.51 4.51 -1.49 2.00
2021-12-31 -1.56 -0.83 -2.29 2.00
2020-12-31 -1.67 -1.65 -1.69 2.00
2020-03-28
NasdaqGM:CATB Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.35
2019-09-30 -2.58
2019-06-30 -2.81
2019-03-31 -3.56
2018-12-31 -5.12
2018-09-30 -6.57
2018-06-30 -10.14
2018-03-31 -11.53
2017-12-31 -12.62
2017-09-30 -14.91
2017-06-30 -17.07
2017-03-31 -20.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Catabasis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Catabasis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Catabasis Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CATB Past Performance

  How has Catabasis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Catabasis Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Catabasis Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Catabasis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Catabasis Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Catabasis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Catabasis Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CATB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -26.29 9.07 18.01
2019-09-30 -25.74 8.58 16.95
2019-06-30 -24.91 8.92 15.94
2019-03-31 -24.26 9.33 14.84
2018-12-31 -25.87 9.84 15.63
2018-09-30 0.25 -25.31 9.76 16.24
2018-06-30 0.50 -26.65 10.13 17.06
2018-03-31 0.50 -27.14 10.20 17.27
2017-12-31 0.50 -27.36 10.18 17.41
2017-09-30 0.25 -30.65 10.86 19.70
2017-06-30 -32.05 10.71 20.93
2017-03-31 -34.52 10.82 23.30
2016-12-31 -36.06 11.13 24.43
2016-09-30 -36.89 11.28 24.94
2016-06-30 -36.95 11.27 24.86
2016-03-31 -35.55 10.50 24.01
2015-12-31 -32.63 9.46 22.20
2015-09-30 -29.05 8.31 19.89
2015-06-30 -26.59 7.34 18.63
2015-03-31 -23.92 7.12 16.45
2014-12-31 -21.88 6.73 14.95
2014-09-30 -20.76 6.91 13.80
2013-12-31 -18.12 4.88 13.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Catabasis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Catabasis Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Catabasis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Catabasis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Catabasis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CATB Health

 How is Catabasis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Catabasis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Catabasis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Catabasis Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Catabasis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Catabasis Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Catabasis Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:CATB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 35.72 0.00 36.24
2019-09-30 38.27 0.00 40.62
2019-06-30 43.36 0.00 46.11
2019-03-31 49.87 0.00 51.66
2018-12-31 34.94 0.00 37.57
2018-09-30 40.52 0.00 43.24
2018-06-30 45.81 0.83 49.93
2018-03-31 12.93 1.66 17.03
2017-12-31 11.79 2.48 16.37
2017-09-30 15.66 3.30 21.71
2017-06-30 21.55 4.11 29.37
2017-03-31 23.96 4.92 31.80
2016-12-31 29.09 5.72 38.53
2016-09-30 36.86 6.52 47.27
2016-06-30 32.81 7.32 42.82
2016-03-31 41.72 8.11 52.58
2015-12-31 50.49 8.89 62.78
2015-09-30 59.54 9.74 72.71
2015-06-30 67.59 9.70 81.55
2015-03-31 13.49 9.66 24.30
2014-12-31 7.20 4.75 14.67
2014-09-30 12.93 4.73 20.65
2013-12-31 27.96 0.00 30.47
  • Catabasis Pharmaceuticals has no debt.
  • Catabasis Pharmaceuticals has no debt compared to 5 years ago when it was 66.1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Catabasis Pharmaceuticals has sufficient cash runway for 1.4 years based on current free cash flow.
  • Catabasis Pharmaceuticals has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 1.3% each year.
X
Financial health checks
We assess Catabasis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Catabasis Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CATB Dividends

 What is Catabasis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Catabasis Pharmaceuticals dividends.
If you bought $2,000 of Catabasis Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Catabasis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Catabasis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CATB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CATB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Catabasis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Catabasis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Catabasis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Catabasis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Catabasis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Catabasis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Catabasis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CATB Management

 What is the CEO of Catabasis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jill Milne
COMPENSATION $1,136,169
AGE 51
TENURE AS CEO 11.8 years
CEO Bio

Ms. Jill C. Milne, PhD is a Co-founder of Catabasis Pharmaceuticals, Inc., has been its President and Chief Executive Officer since June 2008. She served as Principal Financial Officer at Catabasis Pharmaceuticals, Inc. since October 11, 2019 until December 17, 2019 and also served as Principal Financial Officer since April 8, 2016. Ms. Milne co-founded and Senior Director of Biology at Sirtris Pharmaceuticals, Inc. She joined Sirtris from Pfizer Global R&D. As an Associate Director of Biology at Pfizer, she led the biology efforts for a lead discovery group and was head of the Pfizer Drug Pfinder program (www.drugpfinder.com). She has been a Director of Catabasis Pharmaceuticals, Inc since June 2008. Prior to joining Pfizer, she was an ACS Postdoctoral Fellow with Chris Walsh at Harvard Medical School. Ms. Milne received her Ph.D. in Biochemistry from Harvard University and a B.A. in biological chemistry from Wellesley College.

CEO Compensation
  • Jill's compensation has increased whilst company is loss making.
  • Jill's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Catabasis Pharmaceuticals management team in years:

3
Average Tenure
54.5
Average Age
  • The tenure for the Catabasis Pharmaceuticals management team is about average.
Management Team

Jill Milne

TITLE
Co-Founder
COMPENSATION
$1M
AGE
51
TENURE
11.8 yrs

Andy Nichols

TITLE
Chief Scientific Officer
COMPENSATION
$715K
AGE
58
TENURE
3.4 yrs

Joanne Donovan

TITLE
Chief Medical Officer & Senior VP of Clinical Development
COMPENSATION
$827K
AGE
62
TENURE
8.7 yrs

Noah Clauser

TITLE
VP of Finance & Principal Financial Officer
AGE
46
TENURE
0.3 yrs

Andrew Komjathy

TITLE
Chief Commercial Officer
TENURE
0.5 yrs

Andrea Matthews

TITLE
Vice President of Corporate Affairs
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the Catabasis Pharmaceuticals board of directors in years:

4.1
Average Tenure
62.5
Average Age
  • The tenure for the Catabasis Pharmaceuticals board of directors is about average.
Board of Directors

Ken Bate

TITLE
Independent Chairman of the Board
COMPENSATION
$92K
AGE
69
TENURE
4.1 yrs

Jill Milne

TITLE
Co-Founder
COMPENSATION
$1M
AGE
51
TENURE
11.8 yrs

Mike Kishbauch

TITLE
Independent Director
COMPENSATION
$67K
AGE
70
TENURE
3.9 yrs

Gregg Lapointe

TITLE
Independent Director
AGE
60
TENURE
1.2 yrs

Mike Jirousek

TITLE
Member of Scientific Advisory Board
COMPENSATION
$590K
AGE
60
TENURE
4.4 yrs

Eric Brass

TITLE
Member of Scientific Advisory Board

Roger Ulrich

TITLE
Member of Scientific Advisory Board

Jay Horton

TITLE
Member of Scientific Advisory Board

John Kastelein

TITLE
Member of Scientific Advisory Board
AGE
65

Sekar Kathiresan

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Catabasis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Catabasis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CATB News

Simply Wall St News

Can We See Significant Institutional Ownership On The Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Share Register?

Catabasis Pharmaceuticals is a smaller company with a market capitalization of US$73m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Catabasis Pharmaceuticals NasdaqGM:CATB Ownership Summary, August 28th 2019 What Does The Institutional Ownership Tell Us About Catabasis Pharmaceuticals? … As you can see, institutional investors own 39% of Catabasis Pharmaceuticals.

Simply Wall St -

Did Changing Sentiment Drive Catabasis Pharmaceuticals's (NASDAQ:CATB) Share Price Down A Painful 78%?

View our latest analysis for Catabasis Pharmaceuticals Catabasis Pharmaceuticals recorded just US$250,000 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … When it last reported its balance sheet in March 2019, Catabasis Pharmaceuticals had cash in excess of all liabilities of US$47m. … With the share price down 40% per year, over 3 years, it seems likely that the need for cash is weighing on investors' minds.

Simply Wall St -

Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Salary Compare Well With Others?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Jill Milne's Compensation Compare With Similar Sized Companies. … has a market cap of US$111m, and is paying total annual CEO compensation of US$633k.

Simply Wall St -

What Kind Of Shareholders Own Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)?

The big shareholder groups in Catabasis Pharmaceuticals, Inc. … (NASDAQ:CATB) have power over the company. … Catabasis Pharmaceuticals is a smaller company with a market capitalization of US$65m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Before You Buy Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Consider Its Volatility

(NASDAQ:CATB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).

Simply Wall St -

Does Catabasis Pharmaceuticals Inc's (NASDAQ:CATB) Earnings Growth Make It An Outperformer?

Below, I will examine Catabasis Pharmaceuticals Inc's (NASDAQ:CATB) track record on a high level, to give you some insight into how the company has been performing against its long term trend and its industry peers. … View our latest analysis for Catabasis Pharmaceuticals Did CATB's recent earnings growth beat the long-term trend and the industry? … NasdaqGM:CATB Income Statement May 22nd 18 We can further analyze Catabasis Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Catabasis Pharmaceuticals Inc's (NASDAQ:CATB) Sustainability In Question?

A major red flag for CATB is that its cash generated from its business is less than its outgoing cash expenses. … One reason I do like CATB as a business is its low level of fixed assets on its balance sheet (1.79% of total assets). … A good company is reflected in its financials, and for CATB, the financials don't look good.

Simply Wall St -

Catabasis Pharmaceuticals Inc (NASDAQ:CATB): Are Analysts Optimistic?

Many investors are wondering the rate at which CATB will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for CATB, its year of breakeven and its implied growth rate. … View our latest analysis for Catabasis Pharmaceuticals Expectation from analysts is CATB is on the verge of breakeven. … Next Steps: This article is not intended to be a comprehensive analysis on CATB, so if you are interested in understanding the company at a deeper level, take a look at CATB’s company page on Simply Wall St.

Simply Wall St -

What Should We Expect From Catabasis Pharmaceuticals Inc's (NASDAQ:CATB) Earnings In The Years Ahead?

Catabasis Pharmaceuticals Inc's (NASDAQ:CATB) latest earnings update in September 2017 confirmed company earnings became less negative compared to the previous year's level - great news for investors Investors may find it useful to understand how market analysts view Catabasis Pharmaceuticals's earnings growth trajectory over the next couple of years and whether the future looks brighter. … View our latest analysis for Catabasis Pharmaceuticals Analysts' outlook for next year seems buoyant, with earnings becoming less negative, arriving at $-29.2M in 2018. … The pro of this technique is that we can get a better picture of the direction of Catabasis Pharmaceuticals's earnings trajectory over the long run, irrespective of near term fluctuations, fluctuate up and down.

Simply Wall St -

Should You Be Concerned About Catabasis Pharmaceuticals Inc's (CATB) Risks?

If you are looking to invest in Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … How CATB's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … However, this is the opposite to what CATB’s actual beta value suggests, which is higher stock volatility relative to the market.

Simply Wall St -

CATB Company Info

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company’s lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Details
Name: Catabasis Pharmaceuticals, Inc.
CATB
Exchange: NasdaqGM
Founded: 2008
$70,872,801
17,897,172
Website: http://www.catabasis.com
Address: Catabasis Pharmaceuticals, Inc.
Building 1400E,
Suite B14202,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CATB Common Shares Nasdaq Global Market US USD 25. Jun 2015
DB 209A Common Shares Deutsche Boerse AG DE EUR 25. Jun 2015
Number of employees
Current staff
Staff numbers
27
Catabasis Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:28
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.